3DA) Titanium Alloy Powder Factory Plans – The Market Herald


Find out more about this capital increase

Be the first with news that moves the market

Amaero International Ltd (3DA) secured $11 million to complete the installation and commissioning of the titanium alloy powder plant that the company relies on to bring it to a positive cash position.

The 3D additive manufacturing company is also looking to use the funds to pursue growth opportunities in the United States.

Amaero raised $8.2 million through a placement with institutional investors at an undiscounted issue price of 21 cents per share. The rest came via a senior convertible bond issued to the Pegasus Growth Capital Fund (PGCFI) – the company that led the placement.

Amaero International President David Hanna said Pegasus Chief Executive Hank Holland will join Amaero’s Board of Directors.

“As a trusted and respected player with an incredibly strong outlook in the rapidly evolving 3D/additive manufacturing market, we look forward to pursuing additional strategic transactions to maximize value for our shareholders,” he said. -he declares.

Following the news, shares of Amaero traded up around 12% at 23.5 cents at 2:14 p.m. AEST.

Tombola Gold (to be determined) collected thanks to a second fundraising in three months.

This time, the company raised $10.5 million in a placement with institutional and sophisticated investors at a price of 6 cents, more than double the price of the shares offered during the 3 million raise. February dollars.

Tombola chief executive Byron Miles said the cash meant the company’s flagship gold mine, Mount Freda, was now funded to first gold production – a milestone that remains on track to occur in the next quarter.

You can watch our interview with Byron Miles here at The Deal Room.

The company has a market capitalization of around $50 million and shares are trading at 5.9 cents as of 2:19 p.m. AEST.

Clinical Stage I Cannabinoid and Psychedelic Pharmaceutical Companyncannex (IHL) will issue more than 218 million new shares at 57.3 cents in exchange for 100% of APIRx Pharmaceuticals USA.

The certificate acquisition is equivalent to a $125 million deal.

Incannex CEO and Managing Director Joel Latham said the deal would present both short-term and long-term opportunities for value growth.

APIRx has therapeutic candidates for applications including Parkinson’s disease, restless leg syndrome, and the treatment of pain, skin and eye conditions.

The sale should be finalized before the end of the fiscal year. Incannex has a market capitalization approaching half a billion dollars and shares are up more than 10% today at 40.5 cents at 2:20 p.m. AEST.

To finish, Tyranna Resources (TYX) ceased business operations before raising capital for a proposed acquisition. Details are expected to be released by Monday.

Previous Capitalism Without Capital - Intangible Assets Season 1 Episode 4
Next Nigerian capital market closes trades with a gain of N42.7 billion amid weak equity growth